CORD-19:775b90287b44353bee979abb0970a4666022f86d / 770770-770914 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"Fifteen subjects with symptomatic PAR (Total Nasal Symptom Score, TNSS≥5 out of 12) received VitD (4,000 I.U./day) and placebo each for 6 weeks.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T36127","span":{"begin":0,"end":144},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T36127","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T356","span":{"begin":0,"end":144},"obj":"Sentence"}],"attributes":[{"subj":"T356","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#bf93ec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93eca5"}]}]}}